샘플 요청 목록

 카트 문의
시장보고서
상품코드
1777327

세계의 효소보충요법(ERT) 시장

Enzyme Replacement Therapy
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 378 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 효소보충요법(ERT) 시장은 2030년까지 157억 달러에 도달

2024년에 101억 달러로 추정되는 효소보충요법(ERT) 세계 시장은 2024-2030년간 CAGR 7.7%로 성장하여 2030년에는 157억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 고셔병은 CAGR5.5%를 나타내고, 분석 기간 종료시에는 41억 달러에 이를 것으로 예측됩니다. MPS 분야의 성장률은 분석 기간중 CAGR 9.7%로 추정됩니다.

미국 시장은 27억 달러, 중국은 CAGR11.7%로 성장 예측

미국의 효소보충요법(ERT) 시장은 2024년에 27억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 33억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 11.7%로 추정됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 4.0%와 7.3%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 5.1%를 나타낼 전망입니다.

세계의 효소보충요법(ERT) 시장 - 주요 동향과 촉진요인 정리

효소보충요법(ERT)은 희귀질환 치료를 어떻게 변화시킬까?

효소보충요법(ERT)은 대사 기능 장애로 이어지는 효소 결핍을 해결함으로써 희귀 유전성 질환 치료에 혁명을 일으키고 있습니다. ERT는 고셔병, 파브리병, 폼페병과 같은 리소좀 저장 장애(LSD)에 널리 사용되며, 환자는 정상적인 세포 기능에 필요한 특정 효소가 부족합니다. ERT는 재조합 효소나 생명공학적으로 설계된 효소를 공급함으로써 대사 균형을 회복하고 질병의 진행을 억제하여 환자의 예후를 개선합니다.

유전성 대사질환의 유병률 증가와 생명공학의 발전으로 보다 효과적이고 표적화된 효소 치료법이 개발되고 있습니다. 페그화 효소, 장시간 작용형 ERT 등 제제의 개선으로 치료 효과가 향상되고, 투약 횟수가 감소하고 있습니다. 또한, 신생아 선별검사 프로그램 및 조기 진단 이니셔티브의 확대로 ERT의 혜택을 받을 수 있는 환자를 신속하게 파악할 수 있게 되어 질병 관리와 삶의 질 향상에 기여하고 있습니다.

효소보충요법(ERT)의 미래를 이끌 혁신은 무엇인가?

유전자 치료와 표적 약물 전달의 최근 발전은 효소보충요법(ERT)의 미래를 형성하고 있습니다. 연구진은 효소의 안정성과 조직 침투를 개선하고 치료 효과를 높이는 새로운 약물 제제를 찾고 있습니다. 리포좀 및 나노입자 기반의 전달 시스템은 표적 세포로의 효소 흡수를 개선하고 치료 효과를 제한하는 면역계 반응을 감소시키기 위해 개발되고 있습니다.

CRISPR이나 바이러스 벡터 기반 유전자 치료와 같은 유전자 편집 기술도 ERT의 대체 또는 보완 치료의 가능성으로 연구되고 있습니다. 이러한 접근법은 기능성 유전자를 환자 세포에 도입하여 장기적 또는 영구적인 효소 교정을 목표로 합니다. 생명공학이 계속 발전함에 따라 차세대 효소보충요법(ERT)은 희귀 유전성 질환에 대해 보다 효과적이고 개인화된 내구성 있는 치료 옵션을 제공할 수 있습니다.

효소보충요법(ERT) 시장의 성장을 가속하는 주요 요인은?

효소보충요법(ERT) 시장의 성장은 희귀 유전성 질환에 대한 인식 증가, 바이오 의약품 제조의 발전, 신흥 시장에서의 의료 접근성 확대 등 여러 요인에 기인합니다. 희귀질환 치료에 대한 정부의 특혜와 희귀질환 치료제 지정은 제약사들의 ERT 개발에 대한 투자를 촉진하고 있습니다. 또한, 신생아 선별검사 프로그램 및 유전자 검사 이니셔티브 증가도 조기 진단 및 치료 도입에 기여하고 있습니다.

또한, 세포 배양 기술 및 재조합 단백질 생산과 같은 생물학적 제제 제조의 발전은 효소보충요법(ERT)의 확장성과 경제성을 향상시키고 있습니다. 개인 맞춤형 의료와 정밀치료에 대한 투자 확대는 시장 확대를 더욱 촉진하고 있습니다. 새로운 치료법이 등장하고 있는 가운데, ERT는 희귀질환 관리의 핵심이 될 것이며, 지금까지 치료할 수 없었던 질환을 가진 환자들에게 희망을 가져다 줄 것으로 기대되고 있습니다.

부문

치료 상태(고셔병, MPS, SCID, 폼페병, 파브리병, 기타), 투여 경로(비경구, 경구), 최종사용자(수액센터, 병원, 기타)

조사 대상 기업 예

  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amicus Therapeutics
  • Anthera Pharmaceuticals
  • BioMarin Pharmaceutical Inc.
  • Chiesi Farmaceutici S.p.A.
  • Denali Therapeutics Inc.
  • GC Biopharma
  • Horizon Therapeutics plc
  • JCR Pharmaceuticals Co., Ltd.
  • Pfizer Inc.
  • Protalix BioTherapeutics, Inc.
  • PTC Therapeutics
  • Recordati Rare Diseases Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi
  • Swedish Orphan Biovitrum AB(Sobi)
  • Synageva BioPharma Corp.
  • Takeda Pharmaceutical Company
  • Ultragenyx Pharmaceutical Inc.

AI 통합

당사는 유효한 전문가 컨텐츠와 AI툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계 고유 SLM를 쿼리 하는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.08.04

Global Enzyme Replacement Therapy Market to Reach US$15.7 Billion by 2030

The global market for Enzyme Replacement Therapy estimated at US$10.1 Billion in the year 2024, is expected to reach US$15.7 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2024-2030. Gaucher Disease, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$4.1 Billion by the end of the analysis period. Growth in the MPS segment is estimated at 9.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.7 Billion While China is Forecast to Grow at 11.7% CAGR

The Enzyme Replacement Therapy market in the U.S. is estimated at US$2.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.3 Billion by the year 2030 trailing a CAGR of 11.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global Enzyme Replacement Therapy Market - Key Trends & Drivers Summarized

How Is Enzyme Replacement Therapy Transforming Rare Disease Treatment?

Enzyme replacement therapy (ERT) is revolutionizing the treatment of rare genetic disorders by addressing enzyme deficiencies that lead to metabolic dysfunction. ERT is widely used in lysosomal storage disorders (LSDs), such as Gaucher disease, Fabry disease, and Pompe disease, where patients lack specific enzymes required for normal cellular function. By providing recombinant or bioengineered enzymes, ERT helps restore metabolic balance, reducing disease progression and improving patient outcomes.

The increasing prevalence of inherited metabolic disorders and advancements in biotechnology have led to the development of more effective and targeted enzyme therapies. Improved formulations, including pegylated enzymes and long-acting ERTs, are enhancing treatment efficacy and reducing infusion frequency. Additionally, the expansion of newborn screening programs and early diagnostic initiatives is enabling faster identification of patients who can benefit from ERT, leading to better disease management and improved quality of life.

What Are the Innovations Driving the Future of Enzyme Replacement Therapy?

Recent advancements in gene therapy and targeted drug delivery are shaping the future of enzyme replacement therapy. Researchers are exploring novel drug formulations that improve enzyme stability and tissue penetration, enhancing therapeutic outcomes. Liposomal and nanoparticle-based delivery systems are being developed to improve enzyme uptake by target cells and reduce immune system responses that may limit treatment efficacy.

Gene editing technologies such as CRISPR and viral vector-based gene therapy are also being investigated as potential alternatives or complementary treatments to ERT. These approaches aim to provide long-term or permanent enzyme correction by introducing functional genes into patient cells. As biotechnology continues to advance, the next generation of enzyme replacement therapies may offer more effective, personalized, and durable treatment options for rare genetic disorders.

What Are the Key Factors Driving Growth in the Enzyme Replacement Therapy Market?

The growth in the enzyme replacement therapy market is driven by several factors, including increasing awareness of rare genetic disorders, advancements in biopharmaceutical manufacturing, and expanding healthcare access in emerging markets. Government incentives and orphan drug designations for rare disease treatments are encouraging pharmaceutical companies to invest in ERT development. The rise in newborn screening programs and genetic testing initiatives is also contributing to early diagnosis and treatment adoption.

Additionally, advancements in biologics manufacturing, including cell culture technologies and recombinant protein production, are improving the scalability and affordability of enzyme replacement therapies. The growing investment in personalized medicine and precision therapeutics is further driving market expansion. As new treatment approaches emerge, ERT is expected to remain a cornerstone of rare disease management, offering hope to patients with previously untreatable conditions.

SCOPE OF STUDY:

The report analyzes the Enzyme Replacement Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapeutic Condition (Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease, Others); Administration Route (Parenteral, Oral); End-Use (Infusion Centers, Hospitals, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amicus Therapeutics
  • Anthera Pharmaceuticals
  • BioMarin Pharmaceutical Inc.
  • Chiesi Farmaceutici S.p.A.
  • Denali Therapeutics Inc.
  • GC Biopharma
  • Horizon Therapeutics plc
  • JCR Pharmaceuticals Co., Ltd.
  • Pfizer Inc.
  • Protalix BioTherapeutics, Inc.
  • PTC Therapeutics
  • Recordati Rare Diseases Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi
  • Swedish Orphan Biovitrum AB (Sobi)
  • Synageva BioPharma Corp.
  • Takeda Pharmaceutical Company
  • Ultragenyx Pharmaceutical Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Enzyme Replacement Therapy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Rare Lysosomal Storage Disorders Propels Demand for Enzyme Replacement Therapies
    • Advancements in Genomic Research Strengthen the Business Case for Personalized ERT Approaches
    • Increasing Awareness and Early Diagnosis of Rare Diseases Accelerates Demand for Therapeutic Enzymes
    • Regulatory Incentives and Orphan Drug Designations Expand Addressable Market Opportunities
    • Integration of Biomarker-Based Diagnostic Tools Drives Adoption of Tailored ERT Protocols
    • Innovations in Recombinant DNA Technology Spur Growth in Novel ERT Product Development
    • Strategic Collaborations Between Biotech Firms and Academia Accelerate Pipeline Expansion
    • Expansion of Healthcare Access in Emerging Markets Throws the Spotlight on Unmet Treatment Needs
    • Rapid Technological Advancements in Drug Delivery Systems Drive Patient Compliance and Market Uptake
    • Increasing Funding for Rare Disease Research Sustains Long-Term Growth Prospects for ERT
    • Favorable Reimbursement Policies in Developed Markets Strengthen the Business Case for Commercial Launches
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Enzyme Replacement Therapy Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Enzyme Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Enzyme Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Gaucher Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Gaucher Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Gaucher Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for MPS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for MPS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for MPS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for SCID by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for SCID by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for SCID by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pompe Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Pompe Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Pompe Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Fabry Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Fabry Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Fabry Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Therapeutic Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Therapeutic Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Therapeutic Conditions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Infusion Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Infusion Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Infusion Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Enzyme Replacement Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • JAPAN
    • Enzyme Replacement Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • CHINA
    • Enzyme Replacement Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • EUROPE
    • Enzyme Replacement Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Enzyme Replacement Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Enzyme Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • FRANCE
    • Enzyme Replacement Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • GERMANY
    • Enzyme Replacement Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Enzyme Replacement Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Enzyme Replacement Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Enzyme Replacement Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Enzyme Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Enzyme Replacement Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • INDIA
    • Enzyme Replacement Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Enzyme Replacement Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Enzyme Replacement Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Enzyme Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Enzyme Replacement Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Enzyme Replacement Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Enzyme Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • AFRICA
    • Enzyme Replacement Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제